Back to top
more

Chemed (CHE)

(Real Time Quote from BATS)

$425.47 USD

425.47
15,632

+2.14 (0.51%)

Updated Aug 5, 2025 11:00 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

4 Growth Stocks to Pick From a Choppy MedTech Market

by Zacks Equity Research

In the wake of the volatile political scenario and taking a few favorable metrics into account, these MedTech stocks stand out as the most suitable picks.

    Zacks Equity Research

    DaVita (DVA) Surges: Stock Moves 13.6% Higher

    by Zacks Equity Research

    DaVita (DVA) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes

      Zacks Equity Research

      Chemed Banks on Roto-Rooter Sales, Focuses on Vitas Revival

      by Zacks Equity Research

      Chemed (CHE) continues to display robust performance in Roto-Rooter business on strength in core plumbing and drain cleaning service segments.

        Zacks Equity Research

        Align Technology Rides High on InvisAlign & Strategic Pacts

        by Zacks Equity Research

        Rising demand for InvisAlign products in the global teen market and the distribution agreement with Patterson Dental are major upsides for Align (ALGN).

          Zacks Equity Research

          Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources

          by Zacks Equity Research

          Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources

            Tirthankar Chakraborty headshot

            5 of the Most Efficient Stocks to Boost Your Portfolio

            by Tirthankar Chakraborty

            Company with a favorable efficiency level generally provides impressive returns as it is believed to be positively correlated with the stock's price performance.

              Zacks Equity Research

              Envision Healthcare Down More Than 50% This Year, Here's Why

              by Zacks Equity Research

              Envision Healthcare (EVHC) seems to be bogged down by soft patient volumes, increasing expenses and high leverage.

                Zacks Equity Research

                Chemed (CHE) Up 13.6% Since Earnings Report: Can It Continue?

                by Zacks Equity Research

                Chemed (CHE) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Zacks Equity Research

                  Envision Healthcare Hits 52-Week Low on Q3 Miss, Grim View (Revised)

                  by Zacks Equity Research

                  Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.

                    Zacks Equity Research

                    Envision Healthcare Hits 52-Week Low on Q3 Loss, Grim View

                    by Zacks Equity Research

                    Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.

                      Zacks Equity Research

                      Envision Healthcare Continues to Expand Physician Services

                      by Zacks Equity Research

                      Envision Healthcare's (EVHC) numerous acquisitions and management changes are aimed at growing its physician services segment.

                        Zacks Equity Research

                        STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat

                        by Zacks Equity Research

                        STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.

                          Zacks Equity Research

                          AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                          by Zacks Equity Research

                          AmerisourceBergen Corporation's (ABC) expects tepid performance from PharMEDium due to pricing pressure in the generic drug space.

                            Zacks Equity Research

                            CVS Health Gains on Pharmacy Services, Retail Remains a Drag

                            by Zacks Equity Research

                            CVS Health (CVS) benefits from strong Pharmacy Services numbers and continues to deliver solid PBM selling seasons. Retail performance stays sluggish on several headwinds.

                              Brian Bolan headshot

                              Omnova Solutions and Chemed are Zacks Aggressive Growth Rank Buys

                              by Brian Bolan

                              OMN and CHE are profiled as aggressive growth stocks.

                                Zacks Equity Research

                                Why Is Chemed (CHE) Down 7.8% Since the Last Earnings Report?

                                by Zacks Equity Research

                                Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Zacks Equity Research

                                  Here's Why You Must Add Chemed (CHE) Stock to Your Portfolio

                                  by Zacks Equity Research

                                  Chemed Corporation's (CHE) promising Roto-Rooter revenue outlook as well as an increased bottom-line guidance bode well of the company's future.

                                    Zacks Equity Research

                                    Zacks.com featured highlights: Arkema SA, Nutrisystem, Braskem SA, Chemed and SP Plus

                                    by Zacks Equity Research

                                    Zacks.com featured highlights: Arkema SA, Nutrisystem, Braskem SA, Chemed and SP Plus

                                      Zacks Equity Research

                                      5 Top Stocks With Solid Net Profit Margin

                                      by Zacks Equity Research

                                      Net profit is the amount a company retains after deducting all costs, interest, depreciation, taxes and other expenses.

                                        Zacks Equity Research

                                        Envision Healthcare Hurt by High Debt, Increasing Expenses

                                        by Zacks Equity Research

                                        Envision Healthcare's (EVHC) increasing debt and expenses continue to hurt. Further guidance cut by the company is concerning.

                                          Zacks Equity Research

                                          Zacks.com featured highlights: Arkema, Nutrisystem, SYNNEX, Ituran Location and Control and Chemed

                                          by Zacks Equity Research

                                          Zacks.com featured highlights: Arkema, Nutrisystem, SYNNEX, Ituran Location and Control and Chemed

                                            Zacks Equity Research

                                            5 Top Stocks with Stellar Net Profit Margin

                                            by Zacks Equity Research

                                            Net profit is the amount a company retains after deducting all costs, interest, depreciation, taxes and other expenses.

                                              Zacks Equity Research

                                              Chemed (CHE) Q2 Earnings & Revenues Rise Y/Y, View Revised

                                              by Zacks Equity Research

                                              Chemed (CHE) rides high on Roto-Rooter in second-quarter 2017. An encouraging bottom-line projection raises hopes.

                                                Zacks Equity Research

                                                Chemed (CHE) Up 6.4% Since Earnings Report: Can It Continue?

                                                by Zacks Equity Research

                                                Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Zacks Equity Research

                                                  Amedisys (AMED) Catches Eye: Stock Gains 6.2% in Session

                                                  by Zacks Equity Research

                                                  Amedisys, Inc. (AMED) moved big last session, as its shares rose over 6% on the day.